Compare SWX & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SWX | PTCT |
|---|---|---|
| Founded | 1931 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.7B |
| IPO Year | 2017 | 2006 |
| Metric | SWX | PTCT |
|---|---|---|
| Price | $90.48 | $83.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 17 |
| Target Price | ★ $87.40 | $80.65 |
| AVG Volume (30 Days) | 500.3K | ★ 1.9M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | 120.29 | ★ 264.48 |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $5,433,972,000.00 | $264,734,000.00 |
| Revenue This Year | $18.48 | N/A |
| Revenue Next Year | $2.61 | $17.70 |
| P/E Ratio | $46.65 | ★ N/A |
| Revenue Growth | 9.56 | ★ 36.19 |
| 52 Week Low | $72.43 | $43.18 |
| 52 Week High | $94.43 | $87.50 |
| Indicator | SWX | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 58.42 | 68.32 |
| Support Level | $87.14 | $73.41 |
| Resistance Level | $93.93 | $87.50 |
| Average True Range (ATR) | 1.46 | 3.06 |
| MACD | 0.29 | 1.01 |
| Stochastic Oscillator | 90.44 | 79.99 |
Southwest Gas Holdings Inc is a utility company engaged in the purchasing, distributing, and transporting of natural gas in the American Southwest. The company segments its activities into natural gas distribution segment. The Natural gas distribution segment encompasses the company's core natural gas business as distributors in the states of Arizona and Nevada. Its division is responsible for roughly half of Southwest Gas' total revenue through the sale of natural gas to mainly residential and small commercial customers.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.